WO2017052355A3 - Use of peptide drugs for the treatment of osteoporosis and for bone regeneration - Google Patents

Use of peptide drugs for the treatment of osteoporosis and for bone regeneration Download PDF

Info

Publication number
WO2017052355A3
WO2017052355A3 PCT/MX2016/000093 MX2016000093W WO2017052355A3 WO 2017052355 A3 WO2017052355 A3 WO 2017052355A3 MX 2016000093 W MX2016000093 W MX 2016000093W WO 2017052355 A3 WO2017052355 A3 WO 2017052355A3
Authority
WO
WIPO (PCT)
Prior art keywords
osteoporosis
treatment
peptides
bone regeneration
peptide drugs
Prior art date
Application number
PCT/MX2016/000093
Other languages
Spanish (es)
French (fr)
Other versions
WO2017052355A2 (en
Inventor
Higinio Arzate
Fabiola SALGADO CHAVARRÍA
Gonzalo MONTOYA AYALA
Original Assignee
Universidad Nacional Autónoma de México
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/865,909 external-priority patent/US20170088584A1/en
Application filed by Universidad Nacional Autónoma de México filed Critical Universidad Nacional Autónoma de México
Publication of WO2017052355A2 publication Critical patent/WO2017052355A2/en
Publication of WO2017052355A3 publication Critical patent/WO2017052355A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides osteogenic peptides derived from cementum attachment protein (HACD1/CAP) and another derived from cementum protein 1 (CEMP1), and pharmaceutical compositions of said peptides for the prevention and treatment of osteopenia and osteoporosis. These peptides increased bone mineral density in an osteoporotic model, without side effects in vivo, demonstrating clinical effectiveness in the prevention and treatment of osteopenia and osteoporosis in vivo, as well as in bone repair and/or regeneration.
PCT/MX2016/000093 2015-09-25 2016-09-26 Use of peptide drugs for the treatment of osteoporosis and for bone regeneration WO2017052355A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/865,909 US20170088584A1 (en) 2015-09-25 2015-09-25 Use of peptidic drugs for osteoporosis treatment and bone regeneration
US14/865,909 2015-09-25
MX2015016238A MX369939B (en) 2015-09-25 2015-11-25 Use of peptidic drugs for osteoporosis treatment and bone regeneration.
MXMX/A/2015/016238 2015-11-25

Publications (2)

Publication Number Publication Date
WO2017052355A2 WO2017052355A2 (en) 2017-03-30
WO2017052355A3 true WO2017052355A3 (en) 2017-05-26

Family

ID=58386544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2016/000093 WO2017052355A2 (en) 2015-09-25 2016-09-26 Use of peptide drugs for the treatment of osteoporosis and for bone regeneration

Country Status (1)

Country Link
WO (1) WO2017052355A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009013369A (en) * 2009-12-08 2011-06-15 Univ Mexico Nacional Autonoma Tissue engineering for the formation of radicular cementum, bone, dentine, cartilage and periodontal ligament by using human cementum protein 1 (cemp-1).
MX2012005314A (en) * 2012-05-07 2013-11-27 Univ Mexico Nacional Autonoma Biologically active peptide for repairing and regenerating bone.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009013369A (en) * 2009-12-08 2011-06-15 Univ Mexico Nacional Autonoma Tissue engineering for the formation of radicular cementum, bone, dentine, cartilage and periodontal ligament by using human cementum protein 1 (cemp-1).
MX2012005314A (en) * 2012-05-07 2013-11-27 Univ Mexico Nacional Autonoma Biologically active peptide for repairing and regenerating bone.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALVAREZ-PÉREZ, MARCO ANTONIO ET AL.: "Molecular cloning, expression and immunolocalization of a novel human cementum-derived protein (CP-23).", BONE, vol. 38, no. 3, 2006, pages 409 - 414 and 417-418, XP027908126 *
CARMONA-RODRÍGUEZ, BRUNO ET AL.: "Human Cementum Protein 1 induces expression of bone and cementum proteins by human gingival fibroblasts.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 358, no. 3, 2007, pages 763 - 769, XP025322371 *
PRIEGO, ADRIANA RIVERA; ET AL.: "Producción and caracterización de una proteína recombinante del cemento (CEMP 1) en células de Drosophila melanogaster (DML-2-23).", REVISTA ODONTOLÓGICA MEXICAN A, vol. 17, no. 2, 2013, pages 76 - 80, XP055384163 *
VILLARREAL-RAMÍREZ, EDUARDO ET AL.: "Characterization of recombinant human cementum protein 1 (hrCEMP1): primary role in biomineralization.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 384, no. 1, 2009, pages 49 - 54, XP026115673 *

Also Published As

Publication number Publication date
WO2017052355A2 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX2022005291A (en) Vaccines for treatment and prevention of cancer.
EP4292650A3 (en) Heterocyclic compounds as immunomodulators
MX2020011333A (en) Therapeutic use of bone morphogenetic proteins.
WO2016170348A3 (en) Sarna compositions and methods of use
MX2019000588A (en) Somatostatin modulators and uses thereof.
WO2016060996A3 (en) Interleukin-15 compositions and uses thereof
WO2017023933A3 (en) Peptidomimetic macrocycles
MX2016012262A (en) Cenicriviroc for the treatment of fibrosis.
IL286592A (en) Amino acid compositions for the treatment of liver disease
MX2019010949A (en) Somatostatin modulators and uses thereof.
WO2013186777A3 (en) Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
WO2016100619A3 (en) Treatment and diagnosis of cancer
MX2019003805A (en) Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies.
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
PH12017501070A1 (en) Peptides and their use in the treatment of skin
MX2017016227A (en) Broad-spectrum anti-infective peptides.
WO2020123795A3 (en) Anellosomes for delivering protein replacement therapeutic modalities
MX2020007777A (en) Influenza virus vaccines and uses thereof.
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
MX2022013283A (en) Compositions for colon cleansing and the treatment of gastrointestinal disorders.
BR112016023519A2 (en) wnt / ß-catenin signaling inhibitor, pharmaceutical composition and method of treating and / or preventing a pathology defined by vascular malformation
MX2017010277A (en) Cenicriviroc for the treatment of fibrosis.
EP3626712A3 (en) Liver x receptor (lxr) modulators
PH12020551618A1 (en) Erenumab compositions and uses thereof
MX2015016238A (en) Use of peptidic drugs for osteoporosis treatment and bone regeneration.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16849079

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16849079

Country of ref document: EP

Kind code of ref document: A2